Pradaxa (Dabigatran) Off To A Strong Start

Boehringer-Ingelheim’s new oral anticoagulant dabigatran (Pradaxa) is off to a strong but not spectacular start. Wells Fargo analyst Larry Biegelsen reports that the drug has captured about 5% of the anticoagulant market since its launch last October. In the first quarter of 2011 the drug’s annualized sales were $285 million.

The following charts (reprinted with permission of Wells Fargo)  show the uptake of the drug since launch for total (TRx) and new (NRx) prescriptions, compared to Crestor and Zetia in their initial weeks on the market. (Click to enlarge the charts.)

Speak Your Mind